Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation

Rama Krishna Kancha, Nikolas Von Bubnoff, Cornelius Miething, Christian Peschel, Katharina S. Götze, Justus Duyster*

*Corresponding author for this work
18 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation'. Together they form a unique fingerprint.

Medicine & Life Sciences